Literature DB >> 10752630

Mouse FcgammaRI: identification and functional characterization of five new alleles.

A L Gavin1, E H Leiter, P M Hogarth.   

Abstract

The mouse Fcgr1 gene encoding the high-affinity IgG receptor (FcgammaRI) exists as two known alleles, FcgammaRI-BALB and FcgammaRI-NOD, and these alleles exhibit functional differences. To determine whether other alleles exist in mouse strains, Fcgr1 coding regions from 35 strains of mice were sequenced and a further five alleles were identified. The FcgammaRI-BALB and NOD alleles are now designated the "a" and "d" alleles, respectively. Analysis of the five new alleles revealed that although no polymorphisms were observed in the two leader exons, nucleotide and subsequent amino acid changes were observed in the exons encoding the extracellular domains, and transmembrane and cytoplasmic tail. The cDNA of the seven alleles (a-g) were isolated and transiently transfected into COS cells, and IgG-binding studies were performed. Receptors encoded by four of the five new alleles (b, c, f, g) bound IgG2a with high affinity, displaying IgG binding characteristics similar to the a allele (previously FcgammaRI-BALB). The d allele (previously FcgammaRI-NOD) and the e allele [derived from Mus spretus (SPRET/Ei)] encoded receptors which showed broader specificity by binding monomeric IgG2a, IgG2b, and IgG3.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10752630     DOI: 10.1007/s002510050033

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  7 in total

1.  Variability of the inhibition by total immunoglobulin of in vitro autoantibody-mediated erythrophagocytosis by mouse macrophages.

Authors:  S Léonard; I Pierard; T E Michaelsen; S Izui; P L Masson; J-P Coutelier
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

2.  Both Fcgamma receptor I and Fcgamma receptor III mediate disease in accelerated nephrotoxic nephritis.

Authors:  Ruth M Tarzi; Kevin A Davies; Jill W C Claassens; J Sjef Verbeek; Mark J Walport; H Terence Cook
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

3.  Affinity of human IgG subclasses to mouse Fc gamma receptors.

Authors:  Gillian Dekkers; Arthur E H Bentlage; Tamara C Stegmann; Heather L Howie; Suzanne Lissenberg-Thunnissen; James Zimring; Theo Rispens; Gestur Vidarsson
Journal:  MAbs       Date:  2017-05-02       Impact factor: 5.857

4.  IMMUNOLOGY. An interactive reference framework for modeling a dynamic immune system.

Authors:  Matthew H Spitzer; Pier Federico Gherardini; Gabriela K Fragiadakis; Nupur Bhattacharya; Robert T Yuan; Andrew N Hotson; Rachel Finck; Yaron Carmi; Eli R Zunder; Wendy J Fantl; Sean C Bendall; Edgar G Engleman; Garry P Nolan
Journal:  Science       Date:  2015-07-10       Impact factor: 47.728

5.  Splicing landscape of the eight collaborative cross founder strains.

Authors:  Christina L Zheng; Beth Wilmot; Nicole Ar Walter; Denesa Oberbeck; Sunita Kawane; Robert P Searles; Shannon K McWeeney; Robert Hitzemann
Journal:  BMC Genomics       Date:  2015-02-05       Impact factor: 3.969

6.  FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion.

Authors:  Robert J Oldham; C Ian Mockridge; Sonya James; Patrick J Duriez; H T Claude Chan; Kerry L Cox; Vicentiu A Pitic; Martin J Glennie; Mark S Cragg
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751

7.  Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering.

Authors:  Johan M S van der Schoot; Felix L Fennemann; Michael Valente; Yusuf Dolen; Iris M Hagemans; Anouk M D Becker; Camille M Le Gall; Duco van Dalen; Alper Cevirgel; Jaco A C van Bruggen; Melanie Engelfriet; Tomislav Caval; Arthur E H Bentlage; Marieke F Fransen; Maaike Nederend; Jeanette H W Leusen; Albert J R Heck; Gestur Vidarsson; Carl G Figdor; Martijn Verdoes; Ferenc A Scheeren
Journal:  Sci Adv       Date:  2019-08-28       Impact factor: 14.136

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.